L-carnitine as a novel approach for pain and inflammation relief in rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation.
• The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway and transforming growth factor-beta1 (TGF-β1) are implicated in RA pathogenesis.
• L-carnitine's potential as an adjunct therapy targeting these pathways in RA requires investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of L-carnitine as an add-on therapy for rheumatoid arthritis.
• To assess L-carnitine's impact on clinical symptoms, disease activity, and inflammatory markers.
• To explore potential modulation of the JAK/STAT pathway and TGF-β1 by L-carnitine in RA patients.

Main Methods:

• A 12-week randomized controlled trial involving 46 active RA patients.
• Patients received either standard disease-modifying antirheumatic drugs (DMARDs) or DMARDs plus L-carnitine (1000 mg/day).
• Evaluations included clinical assessments (TJC, SJC, VAS, morning stiffness, DAS28, MHAQ) and laboratory markers (CRP, STAT3, TGF-β1) at baseline and 12 weeks.

Main Results:

• The L-carnitine group demonstrated significant improvements in morning stiffness, pain (VAS), joint counts (TJC, SJC), CRP, DAS28, and MHAQ compared to baseline.
• While STAT3 levels increased in the control group, no significant changes were observed in STAT3 or TGF-β1 within the L-carnitine group.
• No significant within-group changes in STAT3 or TGF-β1 were noted for the L-carnitine group.

Conclusions:

• L-carnitine as an adjunct to DMARDs may improve clinical outcomes and reduce systemic inflammation in RA patients.
• The precise mechanisms by which L-carnitine affects RA, particularly its influence on STAT3 and TGF-β1, require further elucidation.
• L-carnitine shows promise as a supportive therapy for managing rheumatoid arthritis symptoms.